Trademarks and Copyright© The images and information contained in the Site are, to the fullest extent possible, copyrighted and otherwise proprietary. It is the policy of Taro to enforce its intellectual property rights to the fullest extent of the law, including (where applicable) seeking criminal sanctions.

News Release
<< Back
Taro Files Form 6-K Supplementing Its Preliminary Third Quarter and Year-to-Date 2008 Financial Results

HAWTHORNE, N.Y., Dec. 18, 2008 (GLOBE NEWSWIRE) -- Taro Pharmaceutical Industries Ltd. ("Taro," the "Company") (Pink Sheets:TAROF) today filed a Form 6-K with the Securities and Exchange Commission supplementing its press release dated November 11, 2008 by providing in tabular form its preliminary, unaudited financial results for the nine months ended September 30, 2008, and updated information on its liquidity.

Specifically, this filing contains the Company's summary consolidated balance sheets, summary consolidated statements of income, and summary consolidated statements of cashflows for the period ended September 30, 2008, as well as previously filed preliminary, unaudited financial results for 2007. The filing also contains information on Taro's current cash position as well as its net debt position over the past 20 months.

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.

For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com.

The Taro Pharmaceutical Industries Ltd. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4733


Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements that do not describe historical facts and statements that refer or relate to events or circumstances the Company "estimates," "believes," or "expects" to happen, "should" happen, or similar language, and statements with respect to the Company's financial performance, availability of financial information and estimates of financial results and financial information for 2007 and 2008. Although Taro Pharmaceutical Industries Ltd. believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurances that its expectations will be attained. Factors that could cause actual results to differ include the possible unavailability of financial information, completion of the audits of 2006, 2007 and/or 2008, actions of the Company's lenders, creditors and Sun Pharmaceutical Industries Ltd. ("Sun"), including but not limited to the outcome of litigation with Sun, general domestic and international economic conditions, industry and market conditions, changes in the Company's financial position, litigation brought by any party in any court in Israel, the United States, or any country in which Taro operates, regulatory actions and legislative actions in the countries in which Taro operates, and other risks detailed from time to time in the Company's SEC reports, including its Annual Reports on Form 20-F. Forward-looking statements speak only as of the date on which they are made. The Company undertakes no obligations to update, change or revise any forward-looking statement, whether as a result of new information, additional or subsequent developments or otherwise.

CONTACT:  Kekst and Company
          Roanne Kulakoff
          (212) 521-4827
Terms of Use
Privacy Statement
Safe Harbor Statement